撰稿 | 公司研究员胡振鹭资本老将卫哲跨界医疗,圣湘生物8亿并购谋求转型,一场“基因改造”实验正在进行中。体外诊断(IVD)行业的寒冬比预想中更漫长。曾经靠核酸检测业务风光无限的圣湘生物(688289.SH),如今正试图通过一场“跨界联姻”实现逆袭。今年初,前阿里巴巴CEO卫哲正式出任圣湘生物非独立董事。这位55岁的资本老将,将自己二十多年的互联网和投资经验,押注在了一家处于行业下行周期的医疗...
Source Link撰稿 | 公司研究员胡振鹭资本老将卫哲跨界医疗,圣湘生物8亿并购谋求转型,一场“基因改造”实验正在进行中。体外诊断(IVD)行业的寒冬比预想中更漫长。曾经靠核酸检测业务风光无限的圣湘生物(688289.SH),如今正试图通过一场“跨界联姻”实现逆袭。今年初,前阿里巴巴CEO卫哲正式出任圣湘生物非独立董事。这位55岁的资本老将,将自己二十多年的互联网和投资经验,押注在了一家处于行业下行周期的医疗...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.